Skip to main content
HIND
NASDAQ Life Sciences

Subsidiary LiveChain Acquires AI HR Analytics Company Humanyze, Eyes National Exchange Uplisting

Analysis by Wiseek.ai
Sentiment info
Positive
Importance info
8
Price
$3.46
Mkt Cap
$19.586M
52W Low
$1.75
52W High
$305
Market data snapshot near publication time

summarizeSummary

Vyome Holdings' subsidiary, LiveChain, acquired an AI HR analytics company, Humanyze, for $325,000 in stock, aiming for strategic diversification and a potential national exchange uplisting for LiveChain.


check_boxKey Events

  • Subsidiary Acquires AI Company

    LiveChain, an indirect subsidiary of Vyome Holdings, acquired senior secured convertible notes of Humanyze, an AI-enabled HR analytics company, from Remus Capital.

  • Transaction Details

    LiveChain issued 211,200,844 shares of its common stock, valued at approximately $325,000, to Remus Capital for the notes. This represents 25% of LiveChain's fully diluted common stock.

  • Asset Transfer

    Following the acquisition of the notes, LiveChain will assume all assets and operations of Humanyze, satisfying the amounts due under the notes.

  • Strategic Diversification & Uplisting Potential

    This move diversifies Vyome's interests into the AI HR analytics sector, with LiveChain aiming for a potential uplisting to a national exchange, which is expected to benefit Vyome as the majority shareholder.


auto_awesomeAnalysis

This 8-K details a significant strategic move by Vyome Holdings through its indirect subsidiary, LiveChain, Inc. LiveChain acquired senior secured convertible notes of Humanyze, an AI-enabled HR analytics company, for approximately $325,000 in LiveChain common stock. This transaction enables LiveChain to assume Humanyze's assets and operations, diversifying Vyome's portfolio beyond its core life sciences focus into the rapidly growing AI HR space. The acquisition is positioned as a path for LiveChain to potentially uplist to a national exchange, which could create substantial value for Vyome as LiveChain's majority shareholder. The transaction was approved by Vyome's Audit Committee and Board, with related parties recusing themselves.

At the time of this filing, HIND was trading at $3.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.6M. The 52-week trading range was $1.75 to $305.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed HIND - Latest Insights

HIND
Apr 29, 2026, 4:16 PM EDT
Filing Type: 8-K
Importance Score:
7
HIND
Mar 20, 2026, 4:56 PM EDT
Filing Type: PRE 14A
Importance Score:
8
HIND
Mar 18, 2026, 6:38 AM EDT
Filing Type: 10-K
Importance Score:
8
HIND
Feb 25, 2026, 4:15 PM EST
Filing Type: 8-K
Importance Score:
8
HIND
Feb 12, 2026, 9:16 PM EST
Filing Type: 8-K
Importance Score:
9
HIND
Jan 28, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
9